BioSpace News Archive

All-share transaction creates international clinical-stage leader in novel psychedelic therapeutics -

On Friday, August 11, the Be The Match Foundation® celebrated its annual Los Angeles Soiree at the Skirball Cultural Center, an event dedicated to raising critical funds to support patients with life-threatening blood cancers and blood disorders.

Bayer AG and BlueRock Therapeutics LP, a clinical stage cell therapy company and wholly owned independently operated subsidiary of Bayer AG, announced details of the positive data from the Phase I clinical trial for bemdaneprocel, a stem cell derived investigational therapy for treating Parkinson’s disease.

3B Scientific announces that it has reached an agreement to acquire iNNOGING Medical.

Opthea Limited is pleased to announce the successful completion of the institutional component of the capital raising announced on Thursday, 24 August 2023.

Proxygen, a leader in the discovery and development of molecular glue degraders, announced that Fierce Biotech has named it as one of 2023’s “Fierce 15” biotechnology companies.

Theravance Biopharma, Inc. announced new ampreloxetine data in neurogenic orthostatic hypotension will be presented at the 2023 International Congress of Parkinson’s Disease and Movement Disorders, taking place August 27-31, 2023, in Copenhagen, Denmark.

KalVista Pharmaceuticals, Inc. announced the acceptance of multiple abstracts at the 2023 HAEi Regional Conference EMEA meeting taking place in Munich, Germany from September 1-3.

ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced the completion of patient enrollment in its Phase 2 clinical trial of ONL1204 Ophthalmic Solution in patients with macula-off rhegmatogenous retinal detachment (RRD).

Pharma Two B, a private, late-stage pharmaceutical company, today announced that sub-group analysis results from the Phase 3 pivotal clinical trial evaluating P2B001 are being presented at the 2023 The International Parkinson and Movement Disorder Society® annual meeting, August 27-31, in Copenhagen, Denmark.